Details of the Drug Reposition

General Information of This Drug (ID: DMYTTBK)

Drug Name
CX2029   DMYTTBK
Drug Type
Antibody drug conjugate

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Aggressive cancer DISKUCQY 2A00-2F9Z Phase 1/2 [1]
Diffuse large B-cell lymphoma DISSACK3 2A81 Phase 1/2 [1]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03543813) A Phase 1-2, First-in-Human Study of CX-2029 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas (PROCLAIM-CX-2029). U.S.National Institutes of Health.